<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238029</url>
  </required_header>
  <id_info>
    <org_study_id>0907-002</org_study_id>
    <nct_id>NCT01238029</nct_id>
  </id_info>
  <brief_title>Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer</brief_title>
  <acronym>CELAVIE</acronym>
  <official_title>Combinational Therapy of Capecitabine, Lapatinib and Vinorelbine for the Treatment of Patients With her2/Neu Positive, Relapsed or Metastatic Breast Carcinoma Following Treatment Failure With Trastuzumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sponsor GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitsgemeinschaft fur Internistische Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitskreis Klinische Studien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sponsor GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate safety and efficiency of the triple combination of&#xD;
      capecitabine, lapatinib and vinorelbine in patients with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of lapatinib with capecitabine ist a standard therapy für Her2 positive&#xD;
      metastatic breast cancer. This study combines this therapy with the additional antimitotic&#xD;
      mode of function by vinorelbine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    new methods of treatment, no more patients appilicable for study&#xD;
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of maximal tolerable Dose (MTD) of combination with Capecitabine and Lapatinib and Vinorelbine</measure>
    <time_frame>4 months</time_frame>
    <description>Phase I: Identification of Dosis limiting toxicities and maximal tolerable dose for Combinational therapy (Time Frame: within the first 21 days under medication)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement with CT or MRI after three and six cycles and every three months, as long no tumor progression is detected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement with CT or MRI after three and six cycles and every three months, as long no tumor progression is detected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement with CT or MRI after three and six cycles and every three months, as long no tumor progression is detected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement with CT or MRI after three and six cycles and every three months, as long no tumor progression is detected.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>HER2 Positive</condition>
  <condition>First or Second Line Therapy</condition>
  <condition>Failure or Contraindication of Trastuzumab Therapy</condition>
  <arm_group>
    <arm_group_label>Capecitabine, Lapatinib, Vinorelbine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib and Capecitabine and Vinorelbine</intervention_name>
    <description>Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8</description>
    <arm_group_label>Capecitabine, Lapatinib, Vinorelbine</arm_group_label>
    <other_name>Xeloda</other_name>
    <other_name>Tyverb</other_name>
    <other_name>Navirel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Able to comply with the protocol&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Adequate contraception&#xD;
&#xD;
          -  Confirmed Her2/neu-positive, adenocarcinoma of the breast&#xD;
&#xD;
          -  At least one measurable lesion according to RECIST 1.1 criteria&#xD;
&#xD;
          -  First or second chemotherapy after diagnosis of metastasis&#xD;
&#xD;
          -  Lapatinib treatment indicated (adjuvant trastuzumab treatment &lt;12 months ago or&#xD;
             progressive disease with trastuzumab treatment)&#xD;
&#xD;
          -  No signs and symptoms of CHF (chronic heart failure), LVEF (left ventricular ejection&#xD;
             fraction) at study start at least 55%&#xD;
&#xD;
          -  Adequate hepatic and renal function value&#xD;
&#xD;
          -  Adequate hematologic function values&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Concurrent participation in another clinical trial. Prior participation is allowed if&#xD;
             the last study medication was administered more than 4 weeks prior to randomization&#xD;
&#xD;
          -  Asymptomatic with regards to tumor illness&#xD;
&#xD;
          -  Previous treatment with lapatinib, capecitabine or vinorelbine&#xD;
&#xD;
          -  Necessity of planned treatment with other chemotherapeutics oder anti-hormone therapy&#xD;
&#xD;
          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days&#xD;
             prior to randomization, or anticipation of the need for major surgery during the&#xD;
             course of the study&#xD;
&#xD;
          -  Evidence of cardiovascular disease, e.g. myocardial infection, unstable angina&#xD;
             pectoris or arrhythmia&#xD;
&#xD;
          -  History of vascular or cardiovascular disease within the past 6 months&#xD;
&#xD;
          -  All illnesses that result in malabsorption of oral medication or inability to take&#xD;
             oral medication&#xD;
&#xD;
          -  Concurrent treatment with anti-viral drugs based on sorivudine or with aminoglycosides&#xD;
&#xD;
          -  Concurrent treatment with any drug interfering with study medication, especially,&#xD;
             those that induce CYP3A&#xD;
&#xD;
          -  Concurrent treatment with allopurinol&#xD;
&#xD;
          -  Other malignancies (except for basal cell carcinoma of the skin and cervical carcinoma&#xD;
             in situ); patient can be included in the study if no recurrent disease has been&#xD;
             observed for at least 5 years&#xD;
&#xD;
          -  Concurrent illnesses or other circumstances that could interfere with trial&#xD;
             participation, efficacy or safety of the patient&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Soeling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethestr. 47, 34119 , Kassel, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <state>Baden-Württemberg</state>
        <zip>88214</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft Dres. Siehl und Söling</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Goslar</city>
        <state>Niedersachsen</state>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Leer Emden</name>
      <address>
        <city>Leer</city>
        <state>Niedersachsen</state>
        <zip>26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis Hämatologie / Onkologie</name>
      <address>
        <city>Stade</city>
        <state>Niedersachsen</state>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkodok (Dr. Rösel und Dr. Depenbusch)</name>
      <address>
        <city>Guetersloh</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33332</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie und Onkologie</name>
      <address>
        <city>Mulheim an der Ruhr</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45468</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Onkologie u. Hämatologie</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis Dörfel/Göhler</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2010</study_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dose finding study</keyword>
  <keyword>Combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

